Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
31 Enero 2024 - 7:00AM
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical
company focused on developing and commercializing novel treatments
for gastrointestinal diseases, announced today that members of the
management team will participate in a fireside chat at the
Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on
Wednesday, February 7, 2024, at 1:30 p.m. ET.
Company management will also participate in one-on-one meetings
during the conference, which will run from February 7-8, 2024.
To access the live webcast and an archived recording of the
event, visit the News & Events section of the Phathom website
at
https://investors.phathompharma.com/news-events/events-and-presentations.
Recordings will be available for 90 days following the conclusion
of the meeting.
About Phathom Pharmaceuticals,
Inc. Phathom Pharmaceuticals is a biopharmaceutical
company focused on the development and commercialization of novel
treatments for gastrointestinal diseases. Phathom has in-licensed
the exclusive rights in the U.S., Europe, and Canada to vonoprazan,
a first-in-class potassium-competitive acid blocker (PCAB). For
more information about Phathom, visit the Company’s website
at www.phathompharma.com and follow the Company on LinkedIn
and X.
MEDIA CONTACTNick
Benedetto1-877-742-8466media@phathompharma.com
INVESTOR CONTACTEric
Sciorilli1-877-742-8466ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved.
Phathom Pharmaceuticals (NASDAQ:PHAT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Phathom Pharmaceuticals (NASDAQ:PHAT)
Gráfica de Acción Histórica
De May 2023 a May 2024